Pharmasset Inc. (fka VRUS)

[surf1944]

7:03AM Pharmasset nominates PSI-938 as a new nucleotide analog inhibitor of hepatitis C for preclinical development (VRUS) 11.22 : Co announces the nomination of PSI-352938 as a lead development candidate from two series of purine analogs for the treatment of chronic hepatitis C virus infection. PSI-938 is a proprietary nucleotide analog polymerase inhibitor of HCV that is being advanced into studies required for submission of an Investigational New Drug application with the FDA or equivalent foreign regulatory application.